Newsletter

**Set to Begin First Ovarian Cancer Study Test Site for Metabolic Disruption Technology (MDT) Combination Therapy**

Viral Genetics’ P-IND Clears FDA To Commence Clinical Trials in Humans

 Set to Begin First Ovarian Cancer Study Test Site for Metabolic Disruption Technology (MDT) Combination Therapy

A physician-initiated Investigational New Drug (P-IND) application submitted to the FDA in late April, 2012, has cleared the FDA’s screening process with the requirement for a regular IND application being waived, resulting in the company being able to begin the first of at least two proposed clinical trial sites to investigate a potential oncology treatment developed from Viral Genetics’ (Pinksheets:VRAL.PK - News) Metabolic Disruption Technology (MDT), which is licensed exclusively to the Company. The P-IND – part of a larger, coordinated research effort – was submitted by the first test site at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio, which includes patient enrollment at Scott and White Hospital (S&W) in Temple, Texas. Additional test sites may also be added in the future.
Read The Full Release

Viral Genetics, Inc. (OTCPK: VRAL) is a biotechnology research and development company researching new treatments and methods of detection for HIV/AIDS, Lyme Disease, staph and strep, cancer and certain other autoimmune and infectious diseases. Two approaches based on patent rights licensed from the University of Colorado and University of Vermont form the basis of our research: "Targeted Peptides" and "Metabolic Disruption". As we near completion of our preclinical research, we are preparing pre-IND applications for FDA clinical trials of compounds from these approaches in the US.

VRAL's vision is to build on the innovative research being conducted by Dr. M. Karen Newell- Rogers, by developing the technology from the laboratory stage through to clinical trials and seeking partners for late-stage clinical development. Dr. Newell-Rogers's work in the areas of Targeted Peptides Technology (TPT) and Metabolic Disruption Technology (MDT) are revealing new facets of many diseases and the body?s response to them. In doing so, we believe that her work is outlining solutions to some of the world's major health challenges including HIV/AIDS, drug-resistant cancers and autoimmune disease. 

Viral Genetics entered into a series of agreements with the University of Colorado and Dr. Newell-Rogers that, over time and after much successful hard work, culminated in the two Exclusive License Agreements that now form the basis of our intellectual property portfolio and our ongoing R&D efforts. Part of this included expanding our technology to include a new line of research relating to Metabolic Disruption (MDT) - an area that holds promise in cancer therapy, wound healing and - to our surprise - production of plant oils and biofuels.  

 VRAL is now focused on initiating clinical trial testing of compounds for HIV/AIDS, Lyme Disease, Staphylococcus, Streptococcus and Sepsis infection, glioblastoma (a form of brain cancer), and more. We are also commencing development of the biofuels applications of the MDT patents through our separate subsidiary, VG Energy.

 About Viral Genetics, Inc. 

 Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com.   

 About VG Energy 

 VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc. Using its Metabolic Disruption Technology (MDT), Viral Genetics' cancer research led to discoveries with major consequences in a wide variety of other industries, including production of biofuel and vegetable oils. VG Energy holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. Application of MDT technology to the biofuel industry could potentially allow it to overcome its major obstacle in the area of production efficiency: namely, an increase in production yields leading to feasible economic returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit www.vgenergy.net.

Research reports: http://www.viralgenetics.com/investors/researchreports.php

Video Interview
 https://www.youtube.com/watch?v=9au7SL56mck

 Keep your eye on VRAL today!

~Jason

Get your alert a full 24 hours before regular subscribers by texting "pennys" to "69302" or go to SMS ALERTS  That means you get in early!!!

 Forward this message to a friend

This report is for information purposes only, and is neither a solicitation or recommendation to b_u_y nor an offer to sell securities. The Bull Report is not a registered investment advisor. The Bull Report is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no li_ability for any losses arising from an investor's reliance on the use of this material. The Bull Report has been compensated ninety thousand dollars from a third pa_rty for coverage of VRAL. The Bull Report and its affiliates or officers currently hold no shares of VRAL. The Bull Report and its affiliates or officers will pur_chase and sell shares of common stock of VRAL, in the open market at any time without notice. The Bull Report will not update its purchases and sales of VRAL in any future postings on our websites. Certain information included herein is forward-looking within the context of the Pri_vate Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.

 If you no longer wish to receive these emails, please reply to this message with "Unsubscribe" in the subject line or simply click on the following link:    Unsubscribe 

 The Bull Report
 4846 Rosemead #104
 Dallas, Texas 75007
 US

Read the VerticalResponse marketing policy.

Stocks covered:	Compensation:	Avg $ Volume for Period:
VRAL	$15000	UNKNOWN
Max Profit: 7.39 %	Gain at close: 0.00 %
*We think that this promoter is a part of a group of promoters.

Newsletter

Turn your attention to VRAL May 22, 2012 07:14